Limits...
The effect of chronic administration of safranal on systolic blood pressure in rats.

Imenshahidi M, Razavi BM, Faal A, Gholampoor A, Mousavi SM, Hosseinzadeh H - Iran J Pharm Res (2015)

Bottom Line: The duration of effect of safranal on SBP, was also evaluated.The data also showed that antihypertensive effects of safranal did not persist.In summary, our results showed that safranal exhibits antihypertensive and normalizing effect on BP in chronic administration.

View Article: PubMed Central - PubMed

Affiliation: Pharmaceutical Research Center, Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

ABSTRACT
Safranal, the main component of Crocus sativus essential oil, exhibits different pharmacological activities. In this study, the effects of safranal, on blood pressure of normotensive and desoxycorticosterone acetate (DOCA) - salt induced hypertensive rats in chronic administration were investigated. Three doses of safranal (1, 2 and 4 mg/Kg/day) and spironolactone (50 mg/Kg/day) were administrated to the different groups of normotensive and hypertensive rats (at the end of 4 weeks treatment by DOCA-salt) for Five weeks. Then the effects of safranal on mean systolic blood pressure (MSBP) and heart rate (HR) were evaluated using tail cuff method. The duration of effect of safranal on SBP, was also evaluated. Our results indicated that chronic administration of safranal could reduce the MSBP in DOCA salt treated rats in a dose dependent manner. Safranal did not decrease the MSBP in normotensive rats. The data also showed that antihypertensive effects of safranal did not persist. In summary, our results showed that safranal exhibits antihypertensive and normalizing effect on BP in chronic administration.

No MeSH data available.


Related in: MedlinePlus

Mean systolic blood pressure (MSBP) in response to various doses of safranal in normotensive and hypertensive rats at the end of nine weeks. Each value is the mean ± SEM of six experiments. One-way ANOVA, Tukey Krumer, ***P< 0.001vs DOCA plus normal saline treated rats.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4403076&req=5

Figure 2: Mean systolic blood pressure (MSBP) in response to various doses of safranal in normotensive and hypertensive rats at the end of nine weeks. Each value is the mean ± SEM of six experiments. One-way ANOVA, Tukey Krumer, ***P< 0.001vs DOCA plus normal saline treated rats.

Mentions: As shown in Figure 2 the injection of safranal (1, 2 and 4 mg/Kg) decreased the MSBP in hypertensive animals (P < 0.001, respectively), but in normotensive rats, safranal did not reduce the MSBP. The hypotensive effect of safranal was similar to that of spironolactone in different doses.


The effect of chronic administration of safranal on systolic blood pressure in rats.

Imenshahidi M, Razavi BM, Faal A, Gholampoor A, Mousavi SM, Hosseinzadeh H - Iran J Pharm Res (2015)

Mean systolic blood pressure (MSBP) in response to various doses of safranal in normotensive and hypertensive rats at the end of nine weeks. Each value is the mean ± SEM of six experiments. One-way ANOVA, Tukey Krumer, ***P< 0.001vs DOCA plus normal saline treated rats.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4403076&req=5

Figure 2: Mean systolic blood pressure (MSBP) in response to various doses of safranal in normotensive and hypertensive rats at the end of nine weeks. Each value is the mean ± SEM of six experiments. One-way ANOVA, Tukey Krumer, ***P< 0.001vs DOCA plus normal saline treated rats.
Mentions: As shown in Figure 2 the injection of safranal (1, 2 and 4 mg/Kg) decreased the MSBP in hypertensive animals (P < 0.001, respectively), but in normotensive rats, safranal did not reduce the MSBP. The hypotensive effect of safranal was similar to that of spironolactone in different doses.

Bottom Line: The duration of effect of safranal on SBP, was also evaluated.The data also showed that antihypertensive effects of safranal did not persist.In summary, our results showed that safranal exhibits antihypertensive and normalizing effect on BP in chronic administration.

View Article: PubMed Central - PubMed

Affiliation: Pharmaceutical Research Center, Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

ABSTRACT
Safranal, the main component of Crocus sativus essential oil, exhibits different pharmacological activities. In this study, the effects of safranal, on blood pressure of normotensive and desoxycorticosterone acetate (DOCA) - salt induced hypertensive rats in chronic administration were investigated. Three doses of safranal (1, 2 and 4 mg/Kg/day) and spironolactone (50 mg/Kg/day) were administrated to the different groups of normotensive and hypertensive rats (at the end of 4 weeks treatment by DOCA-salt) for Five weeks. Then the effects of safranal on mean systolic blood pressure (MSBP) and heart rate (HR) were evaluated using tail cuff method. The duration of effect of safranal on SBP, was also evaluated. Our results indicated that chronic administration of safranal could reduce the MSBP in DOCA salt treated rats in a dose dependent manner. Safranal did not decrease the MSBP in normotensive rats. The data also showed that antihypertensive effects of safranal did not persist. In summary, our results showed that safranal exhibits antihypertensive and normalizing effect on BP in chronic administration.

No MeSH data available.


Related in: MedlinePlus